Evidence map›Paper›PMID 41560819›Full record

ArticleMaterials today. Bio2026

A novel dual-action drug TJ94 facilitated by lipid nanocrystal formulations targeting neuroprotection and antithrombosis in ischemic stroke.

Yi Chen, Xiang Li, Yong Li, Xiaohui Yang, Jinhui Shi, Ya Yang, Jianqing Peng, Lingling Fan, Lei Tang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yi ChenState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guizhou, 561113, China.
Xiang LiState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guizhou, 561113, China.
Yong LiState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guizhou, 561113, China.
Xiaohui YangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guizhou, 561113, China.
Jinhui ShiState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guizhou, 561113, China.
Ya YangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guizhou, 561113, China.
Jianqing PengState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guizhou, 561113, China.
Lingling FanState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guizhou, 561113, China.
Lei TangState Key Laboratory of Discovery and Utilization of Functional Components in Traditional Chinese Medicine, Guizhou Medical University, Guizhou, 561113, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Platelet aggregation and neuronal injury are central factors underlying the pathogenesis of ischemic stroke (IS), thus dual-acting drugs possessing both antiplatelet and neuroprotective effects are highly needed. We synthesized a novel dual-action drug-TJ94 for neuroprotective and anti-platelet action in IS. To facilitate intravenous administration of TJ94, we developed a lipid nanocrystal formulation (TJ94@LNC) to increase the solubility, brain accumulation and therapeutic of TJ94 effects on IS. Our results clearly indicated that TJ94@LNC has great potential in brain accumulation due to the enrichment of transferrin (Tf) and apolipoprotein A1 (ApoA1) in the protein corona, which might improve the therapeutic effects of TJ94 on middle cerebral artery occlusion/reperfusion (MCAO/R) rats in both the acute and chronic phase of IS. Consistent with the design of TJ94, its therapeutic effects are attributed to its neuroprotective properties, which include inhibiting oxidative stress and apoptosis, as well as its antiplatelet activity. This lipid nanocrystal nanoplatform effectively addresses the brain delivery challenges of TJ94 to synergistically exert dual-functional therapeutic effects. It provides an effective solution for the intravenous injection of lipid-soluble drugs for the treatment of IS. This research presents TJ94@LNC as a promising therapeutic nanoplatform for IS.

Indexed as

AntithrombosisIschemic strokeNanocrystalNeuroprotectionPhospholipid

Identifiers

PMID41560819
PMCPMC12813326

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.